久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
您當(dāng)前的位置: 網(wǎng)站首頁 > 產(chǎn)品展廳 >試劑盒 >BioSim Disitamab ELISA Kit(KDC09601)
BioSim Disitamab ELISA Kit(KDC09601)
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 型號:96 assays
  • 貨號:KDC09601
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-10-23
產(chǎn)品詳請
產(chǎn)地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號 KDC09601
用途 For Research Use Only.
檢測方法 Elisa
CAS編號
保質(zhì)期 1 year
適應(yīng)物種 Disitamab
檢測限 0.156 ug /ml
數(shù)量 99999
包裝規(guī)格 96 assays
標(biāo)記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應(yīng)用 Elisa
是否進(jìn)口


Catalog No.

KDC09601

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Disitamab

Alternative Names

RC48-0, Disitamab Vedotin, CAS: 2185868-98-6

Background

Disitamab vedotin (Aidixi®) is an antibody-drug conjugate comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin is being developed by RemeGen for the treatment of solid tumours, including gastric cancer; Seagen has the right to develop disitamab vedotin globally outside of RemeGen's territory. In June 2021, disitamab vedotin received its first Biologics License Application (BLA) approval in China for the treatment of patients with HER2-overexpressing (defined as IHC2+ or 3+) locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two systemic chemotherapy regimens. Disitamab vedotin as monotherapy or combination therapy is also in clinical development for the treatment of other solid tumours globally, including urothelial cancer in China and the USA, and biliary tract cancer, non-small cell lung cancer and HER2-positive and HER2-low expressing breast cancer in China. This article summarizes the milestones in the development of disitamab vedotin leading to this first approval for locally advanced or metastatic gastric cancer.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗的 創(chuàng)立于法國,專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)






聯(lián)系方式
手機(jī):18162686757
微信掃一掃
苗栗市| 芦溪县| 东乡族自治县| 兴文县| 江川县| 进贤县| 泌阳县| 彭山县| 兴化市| 汝南县| 洛宁县| 罗源县| 庆元县| 靖安县| 民县| 沛县| 富顺县| 乐清市| 西昌市| 太原市| 贵溪市| 呼和浩特市| 勐海县| 巍山| 普洱| 克什克腾旗| 三门县| 怀仁县| 安岳县| 梁河县| 凤庆县| 甘孜县| 中西区| 贵德县| 湟源县| 江西省| 涿州市| 三明市| 天水市| 青川县| 卢龙县|